October 27, 2006 – Vertex reported positive results on VX-950 (telaprevir), its highly anticipated hepatitis C drug; Idenix released solid interim data for another hepatitis C candidate, valopicitabine; Novartis published additional data on Tyzeka, its hepatitis B drug approved by the FDA yesterday; Idenix will begin a two-year collaboration with Metabasis Therapeutics for hepatitis drugs; Schering-Plough touted data from re-treatment of patients who failed earlier hepatitis C regimens; Dendreon said patients with significant CD54 upregulation responded better to prostate cancer immunotherapy Provenge; CellCept from Aspreva failed to meet its endpoints in a myasthenia gravis trial; and the IPO for Catalyst Pharmaceutical failed to price and is now listed as being day to day. The Centient Biotech 200™ dropped 19 points to 3994, a decline of .48%. More details...
